Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NN 841

Next Previous
Search
Drug Profile

NN 841

Alternative Names: NN-841

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NanoNewron
  • Class Antibodies; Antidementias
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 20 Feb 2025 NN 841 is available for licensing as of 20 Feb 2025 (https://325d0580.isolation.zscaler.com/profile/f1651b6c-5a7a-4e25-a61a-66f8cd23da60/zia-session/?controls_id=5df7c950-de6d-4760-a0b1-09a3316b5dc3&region=bom&tenant=2c2f6c39ed9e&user=667c11b9588a73cede32e2c88ad331a2b516947fa22a890f27678629e8d0c749&original_url=https%3A%2F%2Fwww.nanonewron.com%2Finvestors%2F&key=sh-1&hmac=172da5dd51ec4744a22bd3212c80ce230e8c54be4d16c9140462f0d4cfa8921d) NanoNewron pipeline, February 2025
  • 20 Feb 2025 Preclinical trials in Alzheimer's disease in USA (SC), prior to February 2025
  • 20 Feb 2025 Pharmacodynamics data from a preclinical trial in Alzheimer's disease released by NanoNewron

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top